CAR-T treatment of pediatric AML: a long and winding road.

In this issue of Blood, Willier et al explored the differences in immunotarget expression in pediatric (ped) acute myeloid leukemia (AML) compared with adult AML. They identified CD33 and CLEC12A (CLL1) as the best combination for immunotherapy in ped AML. Their findings underscore the need to delineate immunotarget expression levels prior to (pre-)clinical application of chimeric antigen receptor (CAR)-T-cell treatment.(1)